In October 2023, Marta Wosinska and Rena Conti concluded a one-year pilot demonstration of how analytics can inform national technology strategy in biopharmaceuticals. Their demonstration was part of a large, cross-industry pilot titled the National Network for Critical Technology Assessment. Funded by the National Science Foundation's Technology Innovation and Partnerships (TIP) Directorate under the CHIPS Act, this pilot set out to identify and evaluate societal, national, and geostrategic challenges facing the United States and investments in key technologies that could help address those challenges.
Authors
- Acknowledgements and disclosures
- This research was supported by grants from the National Science Foundation and the Sloan Foundation. Conti has also received grant funding from the National Cancer Institute, the Leukemia and Lymphoma Society, Arnold Ventures, the U.S. Veterans Affairs Department, and the National Institute of Drug Abuse, as well as consulting fees from Greylock McKinnon Associates and Keystone Consulting. Other than the aforementioned, the authors did not receive financial support from any firm or person for this article or from any firm or person with a financial or political interest in this article. The authors are not currently an officer, director, or board member of any organization with a financial or political interest in this article.The Brookings Institution is financed through the support of a diverse array of foundations, corporations, governments, individuals, as well as an endowment. A list of donors can be found in our annual reports published online here. The findings, interpretations, and conclusions in this report are solely those of its author(s) and are not influenced by any donation.
- Published in
- United States of America
